Bram Bogaert

Bram Bogaert
Ghent University | UGhent · Department of Pharmaceutics

Master of Pharmacy

About

7
Publications
978
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
187
Citations
Citations since 2016
7 Research Items
187 Citations
201620172018201920202021202201020304050
201620172018201920202021202201020304050
201620172018201920202021202201020304050
201620172018201920202021202201020304050
Introduction
PhD-student at the Ghent Research Group on Nanomedicines (Department of Pharmaceutics, Ghent University) under Prof. dr. Koen Raemdonck and Prof. dr. Stefaan De Smedt. Main focus is the development of a lipid nanoparticle platform for cellular delivery of RNA therapeutics

Publications

Publications (7)
Article
Since the recent clinical approval of siRNA-based drugs and COVID-19 mRNA vaccines, the potential of RNA therapeutics for patient healthcare has become widely accepted. Lipid nanoparticles (LNPs) are currently the most advanced nanocarriers for RNA packaging and delivery. Nevertheless, the intracellular delivery efficiency of state-of-the-art LNPs...
Preprint
Full-text available
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Due to a lack of effective treatments, patients with metastatic disease have a median survival time of 6-12 months. We recently demonstrated that the SAMMSON long non-coding RNA (lncRNA) is essential for uveal melanoma cell survival and that antisense oligonucleotide (...
Article
RNA interference (RNAi) enables highly specific silencing of potential target genes for treatment of pulmonary pathologies. The intracellular RNAi pathway can be activated by cytosolic delivery of small interfering RNA (siRNA), inducing sequence-specific gene knockdown on the post-transcriptional level. Although siRNA drugs hold many advantages ove...
Article
Small nucleic acid (NA) therapeutics, such as small interfering RNA (siRNA), are generally formulated in nanoparticles (NPs) to overcome the multiple extra- and intracellular barriers upon in vivo administration. Interaction with target cells typically triggers endocytosis and sequesters the NPs in endosomes, thus hampering the pharmacological acti...
Article
In article number 1703658, Yuezhou Zhang, Hongbo Zhang, and co‐workers discuss the biomedical applications of DNA‐based materials. Due to the well understood interactions of four types of nucleotides, which serve as the building blocks of DNA, the programmable and versatile structure is readily achieved and multifaceted functionalities are assigned...
Thesis
Introduction: In recent years, several types of nanomaterials have been developed as drug delivery systems, allowing to obtain those with the most favourable pharmacological properties for medicinal treatment. Acetalated dextran (Ac-Dex) is an interesting spherical polymer due to its ability to hydrolyse in acidic conditions, while remaining stable...

Network

Cited By

Projects

Project (1)
Project
In this project I try to optimize lipid nanoparticles for extra-hepatic targeting of RNA therapeutics